ONL Therapeutics
By A2Hub Editorial. Published 2026-04-22. Last updated: 2026-04-22.
At a glance
- Founded: As a University of Michigan Kellogg Eye Center spinout, with founding scientific work by David Zacks and collaborators at U-M
- HQ: Ann Arbor, Michigan
- Stage: Clinical-stage biopharma
- Therapeutic focus: Ocular neuroprotection, with lead programs targeting retinal disease-related vision loss
- Status: Private, clinical-stage
- Website: onltherapeutics.com
The pitch in one line
ONL Therapeutics is the Ann Arbor company developing first-in-class drugs to stop vision loss by protecting the photoreceptors in the back of the eye. Spun out of the University of Michigan Kellogg Eye Center, ONL's lead program is a neuroprotective therapy designed to halt the photoreceptor cell death that drives major retinal diseases.
Founding story: from Kellogg Eye Center to a clinical-stage company
ONL Therapeutics traces its scientific lineage to David Zacks, an ophthalmologist and researcher at the University of Michigan Kellogg Eye Center, and the broader U-M retinal neuroscience research community. Zacks' research focused on the molecular mechanisms by which photoreceptors die in retinal disease. Photoreceptor death is the proximate cause of vision loss in retinal detachment, age-related macular degeneration, retinitis pigmentosa, and a long list of other retinal conditions; if you can intervene in the photoreceptor death pathway, you can in principle slow or stop vision loss across multiple disease etiologies.
The intellectual bet was that a small molecule inhibitor of a specific photoreceptor death pathway could provide neuroprotection in retinal disease independent of the upstream cause. ONL Therapeutics was founded as the commercial vehicle to translate that research into clinical-stage drug development. The company set up in Ann Arbor and has continued to operate from the city as it has progressed through preclinical and clinical development.
What they build
ONL Therapeutics is a drug development company. Its product set is a pipeline of small molecule and biologic therapies targeting the photoreceptor death pathway in retinal disease.
The development pipeline has been led by ONL1204, the company's lead candidate, designed as a Fas inhibitor that protects photoreceptors from cell death. ONL1204 has advanced through preclinical work into clinical trials targeting indications including:
Retinal detachment. A condition where the retina separates from the underlying tissue; even with successful surgical reattachment, photoreceptor death continues to drive vision loss. A neuroprotective therapy administered around the time of reattachment is the kind of indication ONL1204 was designed for.
Geographic atrophy in age-related macular degeneration. A leading cause of irreversible vision loss in older adults; the pathology is photoreceptor and retinal pigment epithelium loss in the macula.
Other retinal indications. The platform mechanism (photoreceptor neuroprotection independent of upstream cause) suggests applicability to additional retinal disease indications, with development priorities driven by clinical and commercial considerations.
The clinical-stage program status, specific trial endpoints, and most recent regulatory milestones should be cross-checked on the ONL Therapeutics website before citing in detail; clinical-stage biopharma timelines move and the latest public reporting is the source of truth.
Funding history
ONL Therapeutics has raised institutional capital across multiple rounds. The investor base has spanned biotech-focused venture and growth funds with an interest in ophthalmology and neuroprotection. Specific funding totals and round details should be verified against current public reporting.
The capital structure of clinical-stage biopharma is different from the capital structure of software companies. ONL Therapeutics' funding has supported the long-cycle work of preclinical development, IND-enabling studies, and the clinical trial program; the path to revenue depends on regulatory approval and commercial launch rather than on near-term recurring revenue.
Ann Arbor footprint
ONL Therapeutics operates from Ann Arbor and represents one of the city's most credible clinical-stage biopharmas. The team is small relative to commercial-stage biopharma, which is typical for the development stage; a clinical-stage company is heavily focused on clinical development, regulatory affairs, and the small number of scientific and operating roles needed to advance the pipeline.
The U-M Kellogg Eye Center connection is direct and ongoing. The Kellogg Eye Center is one of the largest academic ophthalmology programs in the US; it provides scientific advisors, clinical investigators, and a broader research community that anchors ONL's scientific identity.
Leadership and people
The company has been built around the founding scientific team and clinical and operating leadership recruited from the broader biopharma industry. David Zacks remains a public scientific face of the company alongside the operating CEO and clinical leadership. Specific current titles and operating leadership should be verified on the ONL Therapeutics website before citing.
The scientific advisory board and clinical investigator network connect ONL to the broader academic ophthalmology community, particularly through the Kellogg Eye Center relationships. That academic network is a strategic asset; clinical-stage ophthalmology development depends on the participation of leading retinal specialists, and Kellogg's stature inside the field has been useful for recruiting investigators across the multi-site clinical trial program.
The investor and board composition reflects the typical clinical-stage biopharma profile: biotech-focused venture investors with ophthalmology and neuroprotection portfolio experience, plus operational leadership recruited from the broader clinical development industry.
Why it matters
Three reasons ONL Therapeutics matters in the Ann Arbor story.
First, it is one of the most credible clinical-stage biopharmas operating from Ann Arbor outside of the Esperion Therapeutics and HistoSonics anchors. Clinical-stage biopharma is hard, slow, capital-intensive work, and a city's biotech bench is measured in part by how many companies make it to clinical-stage development. ONL is one of the answers for Ann Arbor.
Second, the U-M Kellogg Eye Center spinout lineage maps directly onto the University of Michigan tech startups story. Kellogg is one of the largest academic ophthalmology programs in the US; commercializing its translational research into clinical-stage drug development is the playbook the broader Michigan tech transfer ecosystem has been built to support.
Third, the ophthalmology category is meaningful. Retinal disease is one of the largest unmet need areas in medicine. A neuroprotective therapy that works across multiple retinal indications is the kind of program that, if it succeeds, has the potential to be a category-defining drug. The clinical and regulatory risk is significant; the upside if the program works is also significant.
Related
- Strata Oncology is the other Ann Arbor clinical-and-commercial-stage U-M-spinout in oncology.
- Ripple Science is the Ann Arbor clinical trial recruitment SaaS that supports clinical-stage biopharma operations.
- Akadeum Life Sciences is the Ann Arbor cell sorting company in the broader life sciences cluster.
- The biotech category hub covers the full Ann Arbor biotech bench.
- The companies directory is the master index.
FAQ
Where is ONL Therapeutics headquartered? ONL Therapeutics is headquartered in Ann Arbor, Michigan.
What does ONL Therapeutics do? ONL Therapeutics is a clinical-stage biopharma developing therapies to halt vision loss caused by retinal disease. The lead program targets the photoreceptor cell death pathway, with the intent of providing neuroprotection across multiple retinal indications.
Who founded ONL Therapeutics? ONL traces its scientific lineage to David Zacks, an ophthalmologist and researcher at the University of Michigan Kellogg Eye Center, and the broader U-M retinal neuroscience research community. The company was founded as the commercial vehicle to translate that research into clinical-stage drug development.
What is ONL1204? ONL1204 is ONL Therapeutics' lead clinical candidate, designed as a Fas inhibitor that protects photoreceptors from cell death. The program has been advanced into clinical trials targeting indications including retinal detachment and geographic atrophy in age-related macular degeneration.
What stage is ONL Therapeutics at? ONL is a clinical-stage biopharma. Specific trial status, regulatory milestones, and pipeline details should be verified against current public reporting on the ONL Therapeutics website.
What is the connection between ONL and the University of Michigan Kellogg Eye Center? ONL Therapeutics is a Kellogg Eye Center spinout. The Kellogg Eye Center provides the scientific lineage, ongoing scientific advisors, and clinical investigators connected to ONL's clinical development program.
How much has ONL Therapeutics raised? Cumulative disclosed capital exceeds $85 million across multiple rounds, including a Series B of approximately $47 million in 2021 led by Perceptive Advisors with participation from Canaan Partners, BVF Partners, and InFocus Capital Partners.
Who leads ONL Therapeutics? David Esposito is CEO. David Zacks remains Chief Scientific Officer and a co-founder. Esposito brought operating experience from earlier Michigan-based life-sciences companies including Armune BioScience and has led ONL through its current clinical development phase.
Is ONL Therapeutics hiring? Selectively. Open roles in clinical operations, regulatory affairs, biostatistics, preclinical research, and corporate functions are posted at onltherapeutics.com/careers when available. As a clinical-stage biopharma, hiring is targeted rather than broad-based.
Strategic reading
Ophthalmology biotech has been an active category for both investment and acquisition over the last decade. Regeneron's Eylea franchise (aflibercept), Genentech's Lucentis franchise (ranibizumab) and Vabysmo (faricimab), Novartis' Beovu (brolucizumab), and the newer complement-inhibitor entrants in geographic atrophy (Apellis' SYFOVRE / pegcetacoplan and Astellas / Iveric's IZERVAY / avacincaptad pegol) have established that retinal disease therapies can reach multi-billion-dollar annual revenue in the US market. The large pharma buyers for novel ophthalmology assets are well-defined: Regeneron, Roche / Genentech, Novartis, AbbVie / Allergan, and specialty-focused acquirers.
ONL's mechanism (Fas pathway inhibition for photoreceptor neuroprotection) is differentiated from the anti-VEGF and complement-inhibitor approaches that dominate the current ophthalmology market. If ONL1204 reads out positively in its initial indications, the differentiated mechanism could position the drug for both standalone commercial development and combination use with existing standard-of-care therapies, which would be attractive to a strategic acquirer.
The base-rate risks are real. Neuroprotection programs across the central nervous system have historically had higher clinical failure rates than mechanism-based therapies with visible downstream effects. Retinal drug development is capital-intensive and requires specialized ophthalmology development expertise. ONL has assembled that expertise inside the company and through its scientific advisory network, but the overall category remains high-risk and high-reward.
What to watch. Near-term readouts from the Phase 2 retinal-detachment program are the signal events. A positive efficacy readout on a meaningful clinical endpoint would substantially re-rate the company's strategic optionality. A negative readout would push the program toward indication selection in geographic atrophy or alternative retinal indications, extending the timeline and capital requirements.